ClearPoint Neuro Zukünftiges Wachstum
Future Kriterienprüfungen 2/6
ClearPoint Neuro wird ein Gewinn- und Umsatzwachstum von 11.5% bzw. 27.8% pro Jahr prognostiziert, während der Gewinn pro Aktie um 15.2% pro Jahr wachsen soll.
Wichtige Informationen
11.5%
Wachstumsrate der Gewinne
15.2%
EPS-Wachstumsrate
| Medical Equipment Gewinnwachstum | 16.7% |
| Wachstumsrate der Einnahmen | 27.8% |
| Zukünftige Eigenkapitalrendite | n/a |
| Analystenabdeckung | Low |
| Zuletzt aktualisiert | 20 Jun 2024 |
Jüngste Aktualisierungen zum künftigen Wachstum
ClearPoint Neuro, Inc. (NASDAQ:CLPT) Just Reported First-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?
May 09
Analysts Have Made A Financial Statement On ClearPoint Neuro, Inc.'s (NASDAQ:CLPT) Yearly Report
Mar 15Recent updates
ClearPoint Neuro, Inc. (NASDAQ:CLPT) Just Reported First-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?
May 09ClearPoint Neuro: Macro-Induced Multiple Compression
Apr 25Are ClearPoint Neuro, Inc. (NASDAQ:CLPT) Investors Paying Above The Intrinsic Value?
Apr 19Analysts Have Made A Financial Statement On ClearPoint Neuro, Inc.'s (NASDAQ:CLPT) Yearly Report
Mar 15Should You Investigate ClearPoint Neuro, Inc. (NASDAQ:CLPT) At US$6.18?
Jan 04Does ClearPoint Neuro (NASDAQ:CLPT) Have A Healthy Balance Sheet?
Dec 06Is There An Opportunity With ClearPoint Neuro, Inc.'s (NASDAQ:CLPT) 41% Undervaluation?
Nov 06Is ClearPoint Neuro (NASDAQ:CLPT) Using Debt In A Risky Way?
Aug 18ClearPoint Neuro, Inc. (NASDAQ:CLPT) Looks Just Right With A 40% Price Jump
Apr 17Does ClearPoint Neuro (NASDAQ:CLPT) Have A Healthy Balance Sheet?
Jan 03ClearPoint Neuro: Continuous Great Execution
Sep 19ClearPoint Neuro: Picks & Shovels Galore
Aug 19ClearPoint Neuro (NASDAQ:CLPT) Has Debt But No Earnings; Should You Worry?
Aug 18ClearPoint Neuro: A 'Picks And Shovels' Biotech Company
Jul 25ClearPoint Neuro: Continuous Execution Despite Covid Headwind
May 20Is ClearPoint Neuro (NASDAQ:CLPT) Using Debt In A Risky Way?
Apr 25ClearPoint Neuro: A Strong Recovery Play Once COVID Subsides
Mar 18ClearPoint Neuro (NASDAQ:CLPT) Has Debt But No Earnings; Should You Worry?
Jan 19ClearPoint Neuro: Underlying Growth Potential Concealed By COVID
Jan 14ClearPoint Neuro: Becoming The Neurosurgical Platform Of Choice
Oct 01ClearPoint Neuro: Path To Being The Neurological Navigation Platform Company
Aug 06Health Check: How Prudently Does ClearPoint Neuro (NASDAQ:CLPT) Use Debt?
Jul 19Clearpoint Neuro (CLPT) Investor Presentation - Slideshow
May 28Why We Think Shareholders May Be Considering Bumping Up ClearPoint Neuro, Inc.'s (NASDAQ:CLPT) CEO Compensation
May 27US$35.00 - That's What Analysts Think ClearPoint Neuro, Inc. (NASDAQ:CLPT) Is Worth After These Results
May 13Gewinn- und Umsatzwachstumsprognosen
| Datum | Umsatz | Gewinne | Freier Cashflow | Bargeld aus operativen Tätigkeiten | Durchschn. Anz. Analysten |
|---|---|---|---|---|---|
| 12/31/2026 | 58 | -15 | N/A | N/A | 1 |
| 12/31/2025 | 42 | -17 | -3 | -3 | 3 |
| 12/31/2024 | 31 | -17 | -10 | -10 | 3 |
| 3/31/2024 | 26 | -21 | -13 | -12 | N/A |
| 12/31/2023 | 24 | -22 | -15 | -14 | N/A |
| 9/30/2023 | 22 | -22 | -17 | -16 | N/A |
| 6/30/2023 | 22 | -21 | -19 | -18 | N/A |
| 3/31/2023 | 21 | -18 | -19 | -18 | N/A |
| 12/31/2022 | 21 | -16 | -17 | -16 | N/A |
| 9/30/2022 | 20 | -16 | -18 | -17 | N/A |
| 6/30/2022 | 19 | -16 | -17 | -16 | N/A |
| 3/31/2022 | 17 | -16 | -15 | -15 | N/A |
| 12/31/2021 | 16 | -14 | -13 | -13 | N/A |
| 9/30/2021 | 16 | -12 | -12 | -12 | N/A |
| 6/30/2021 | 15 | -9 | -10 | -10 | N/A |
| 3/31/2021 | 14 | -7 | -8 | -8 | N/A |
| 12/31/2020 | 13 | -7 | -8 | -8 | N/A |
| 9/30/2020 | 12 | -7 | -6 | -6 | N/A |
| 6/30/2020 | 12 | -6 | -6 | -5 | N/A |
| 3/31/2020 | 12 | -6 | -5 | -5 | N/A |
| 12/31/2019 | 11 | -6 | -3 | -3 | N/A |
| 9/30/2019 | 10 | -5 | -3 | -3 | N/A |
| 6/30/2019 | 9 | -5 | -3 | -3 | N/A |
| 3/31/2019 | 8 | -6 | -3 | -3 | N/A |
| 12/31/2018 | 7 | -6 | -5 | -5 | N/A |
| 9/30/2018 | 7 | -7 | -6 | -6 | N/A |
| 6/30/2018 | 7 | -7 | -7 | -6 | N/A |
| 3/31/2018 | 7 | -7 | -7 | -7 | N/A |
| 12/31/2017 | 7 | -7 | N/A | -6 | N/A |
| 9/30/2017 | 7 | -7 | N/A | -5 | N/A |
| 6/30/2017 | 7 | -8 | N/A | -5 | N/A |
| 3/31/2017 | 6 | -8 | N/A | -6 | N/A |
| 12/31/2016 | 6 | -8 | N/A | -6 | N/A |
| 9/30/2016 | 6 | -8 | N/A | -6 | N/A |
| 6/30/2016 | 5 | -5 | N/A | -6 | N/A |
| 3/31/2016 | 5 | -7 | N/A | -7 | N/A |
| 12/31/2015 | 5 | -8 | N/A | -9 | N/A |
| 9/30/2015 | 4 | -9 | N/A | -9 | N/A |
| 6/30/2015 | 3 | -13 | N/A | -10 | N/A |
| 3/31/2015 | 4 | -11 | N/A | -9 | N/A |
| 12/31/2014 | 4 | -5 | N/A | -7 | N/A |
| 9/30/2014 | 4 | -4 | N/A | -7 | N/A |
| 6/30/2014 | 4 | -4 | N/A | -6 | N/A |
| 3/31/2014 | 3 | -4 | N/A | -7 | N/A |
| 12/31/2013 | 4 | -7 | N/A | -8 | N/A |
| 9/30/2013 | 5 | -4 | N/A | -8 | N/A |
Analystenprognosen zum zukünftigen Wachstum
Einkommen vs. Sparrate: CLPT wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.
Ertrag vs. Markt: CLPT wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.
Hohe Wachstumserträge: CLPT wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.
Einnahmen vs. Markt: CLPTDie Einnahmen des Unternehmens (27.8% pro Jahr) werden voraussichtlich schneller wachsen als der Markt US (8.7% pro Jahr).
Hohe Wachstumseinnahmen: CLPTDie Einnahmen des Unternehmens (27.8% pro Jahr) werden voraussichtlich schneller wachsen als 20% pro Jahr.
Wachstumsprognosen für den Gewinn je Aktie
Künftige Eigenkapitalrendite
Künftige Eigenkapitalrendite: Unzureichende Daten, um festzustellen, ob die Eigenkapitalrendite von CLPT in 3 Jahren voraussichtlich hoch sein wird